Shaanxi Meibang Pharmaceutical Group Co., Ltd.
605033.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥2 | CN¥2 | CN¥2 | CN¥4 |
| - Cash | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| + Debt | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Enterprise Value | CN¥1 | CN¥2 | CN¥2 | CN¥3 |
| Revenue | CN¥1 | CN¥1 | CN¥1 | CN¥1 |
| % Growth | 26.7% | -22.8% | 7.5% | – |
| Gross Profit | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| % Margin | 28.5% | 31.6% | 41.6% | 38.3% |
| EBITDA | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| % Margin | 6.7% | 12% | 18.6% | 18.4% |
| Net Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| % Margin | 4.2% | 8.2% | 16% | 14.9% |
| EPS Diluted | 0.27 | 0.43 | 1.07 | 1.14 |
| % Growth | -37.2% | -59.8% | -6.1% | – |
| Operating Cash Flow | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| Capital Expenditures | -CN¥0 | -CN¥0 | -CN¥0 | -CN¥0 |
| Free Cash Flow | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |